Osaic Holdings
ARTV

Osaic Holdings’s Artiva Biotherapeutics ARTV Stock Holding History

Osaic Holdings’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-18
Closed -$116 – 8213
2026
Q1 		$116 Sell
18
-14
-44% -$69 ﹤0.01% 7619
2025
Q4 		$137 Buy
+32
New +$121 ﹤0.01% 7619

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

Osaic Holdings's ARTV Position: Q2 2026 in Review

Osaic Holdings sold out of Artiva Biotherapeutics (ARTV) in Q2 2026, closing a stake of 18 shares — an estimated $116 sold.

Osaic Holdings first reported a position in ARTV in Q4 2025 and held it in 2 quarters. The position peaked at $137 in Q4 2025. 72 funds tracked by Wall St. Rank hold ARTV as of Q2 2026.

  • Osaic Holdings reported no remaining Artiva Biotherapeutics position as of Q2 2026 after selling out during the quarter.
  • Osaic Holdings sold 18 Artiva Biotherapeutics shares in Q2 2026, an estimated $116.
  • Osaic Holdings first reported a position in Artiva Biotherapeutics in Q4 2025 and held it in 2 quarters.
  • Osaic Holdings's Artiva Biotherapeutics position peaked at $137 in Q4 2025.
  • 72 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q2 2026.

Based on Osaic Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.